190 related articles for article (PubMed ID: 38270614)
1. Activation of NOP receptor increases vulnerability to stress: role of glucocorticoids and CRF signaling.
Holanda VAD; de Almeida RN; de Oliveira MC; da Silva Junior ED; Galvão-Coelho NL; Calo' G; Ruzza C; Gavioli EC
Psychopharmacology (Berl); 2024 May; 241(5):1001-1010. PubMed ID: 38270614
[TBL] [Abstract][Full Text] [Related]
2. Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice.
Holanda VAD; Oliveira MC; Da Silva Junior ED; Calo' G; Ruzza C; Gavioli EC
Neurobiol Stress; 2020 Nov; 13():100255. PubMed ID: 33344710
[TBL] [Abstract][Full Text] [Related]
3. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
4. NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.
Holanda VAD; Santos WB; Asth L; Guerrini R; Calo' G; Ruzza C; Gavioli EC
Psychopharmacology (Berl); 2018 Nov; 235(11):3093-3102. PubMed ID: 30145654
[TBL] [Abstract][Full Text] [Related]
5. The nociceptin receptor antagonist [Nphe1,Arg14,Lys15]nociceptin/orphanin FQ-NH2 blocks the stimulatory effects of nociceptin/orphanin FQ on the HPA axis in rats.
Leggett JD; Harbuz MS; Jessop DS; Fulford AJ
Neuroscience; 2006 Sep; 141(4):2051-7. PubMed ID: 16784820
[TBL] [Abstract][Full Text] [Related]
6. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
Gavioli EC; Calo' G
Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
[TBL] [Abstract][Full Text] [Related]
7. Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to inhibit its anorectic effect.
Ciccocioppo R; Cippitelli A; Economidou D; Fedeli A; Massi M
Physiol Behav; 2004 Aug; 82(1):63-8. PubMed ID: 15234592
[TBL] [Abstract][Full Text] [Related]
8. Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats.
Delaney G; Dawe KL; Hogan R; Hunjan T; Roper J; Hazell G; Lolait SJ; Fulford AJ
J Neuroendocrinol; 2012 Dec; 24(12):1527-41. PubMed ID: 22835008
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the NOP receptor signaling affects resilience to acute stress.
Holanda VAD; Pacifico S; Azevedo Neto J; Finetti L; Lobão-Soares B; Calo G; Gavioli EC; Ruzza C
J Psychopharmacol; 2019 Dec; 33(12):1540-1549. PubMed ID: 31337258
[TBL] [Abstract][Full Text] [Related]
10. Endogenous nociceptin / orphanin FQ system involvement in hypothalamic-pituitary-adrenal axis responses: relevance to models of inflammation.
Leggett JD; Dawe KL; Jessop DS; Fulford AJ
J Neuroendocrinol; 2009 Nov; 21(11):888-97. PubMed ID: 19732291
[TBL] [Abstract][Full Text] [Related]
11. Nociceptin/orphanin FQ receptor system blockade as an innovative strategy for increasing resilience to stress.
Gavioli EC; Holanda VAD; Calo G; Ruzza C
Peptides; 2021 Jul; 141():170548. PubMed ID: 33862163
[TBL] [Abstract][Full Text] [Related]
12. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
Asth L; Ruzza C; Malfacini D; Medeiros I; Guerrini R; Zaveri NT; Gavioli EC; Calo' G
Neuropharmacology; 2016 Jun; 105():434-442. PubMed ID: 26867504
[TBL] [Abstract][Full Text] [Related]
13. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test.
Gavioli EC; Marzola G; Guerrini R; Bertorelli R; Zucchini S; De Lima TC; Rae GA; Salvadori S; Regoli D; Calo G
Eur J Neurosci; 2003 May; 17(9):1987-90. PubMed ID: 12752799
[TBL] [Abstract][Full Text] [Related]
14. The nociceptin/orphanin FQ antagonist UFP-101 differentially modulates the glucocorticoid response to restraint stress in rats during the peak and nadir phases of the hypothalamo-pituitary-adrenal axis circadian rhythm.
Leggett JD; Jessop DS; Fulford AJ
Neuroscience; 2007 Jul; 147(3):757-64. PubMed ID: 17574767
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.
Silva EF; Silva AI; Asth L; Souza LS; Zaveri NT; Guerrini R; Calo' G; Ruzza C; Gavioli EC
Behav Brain Res; 2019 Jan; 356():120-126. PubMed ID: 30142397
[TBL] [Abstract][Full Text] [Related]
16. The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus.
D'Oliveira da Silva F; Azevedo Neto J; Sturaro C; Guarino A; Robert C; Gavioli EC; Calo G; Mouledous L; Ruzza C
Neuropharmacology; 2022 Jul; 212():109077. PubMed ID: 35513173
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice.
Gavioli EC; Vaughan CW; Marzola G; Guerrini R; Mitchell VA; Zucchini S; De Lima TC; Rae GA; Salvadori S; Regoli D; Calo' G
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):547-53. PubMed ID: 15197534
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
Rizzi A; Gavioli EC; Marzola G; Spagnolo B; Zucchini S; Ciccocioppo R; Trapella C; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):968-74. PubMed ID: 17329551
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in Nociceptin/Orphanin FQ Peptide Receptor-Mediated Pain and Anxiety Symptoms in a Preclinical Model of Post-traumatic Stress Disorder.
Zhang Y; Schalo I; Durand C; Standifer KM
Front Psychiatry; 2018; 9():731. PubMed ID: 30670988
[TBL] [Abstract][Full Text] [Related]
20. Swim stress enhances nociceptin/orphanin FQ-induced inhibition of rat dorsal raphe nucleus activity in vivo and in vitro: role of corticotropin releasing factor.
Nazzaro C; Barbieri M; Varani K; Beani L; Valentino RJ; Siniscalchi A
Neuropharmacology; 2010 Feb; 58(2):457-64. PubMed ID: 19747494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
